ACTU

0.22535.38%
AK

Alan Kozikowski

Scientific Founder and Advisor

Dr. Alan Kozikowski, Ph.D., is the Scientific Founder and Advisor of Actuate Therapeutics, Inc. Dr. Kozikowski has authored over 550 peer reviewed scientific publications and is a holder of 100 patents. Dr. Kozikowski served as Chief Science Officer of Bright Minds Biosciences Inc. since October 29, 2020 until June 26, 2022 and had been its Director since September 29, 2020 until September 6, 2022. Dr. Kozikowski trained at Michigan, Berkeley, and Harvard, began his career as an organic chemist at the University of Pittsburgh. Following his interests in the applications of chemistry to biological problems, he moved on to the Mayo Clinic, and then assumed a position at the Georgetown University Medical Center as Director of the Drug Discovery Program. He has also developed a new Positron Emission Tomography (PET) imaging agent for use in prostate cancer diagnosis, which is in the clinic. After a decade at Georgetown, he led a research group at the University of Illinois at Chicago in the Department of Medicinal Chemistry. Dr. Kozikowski has experience running biotechnology companies including Chief Executive Officer of Starwise Therapeutics developing novel HDAC6 inhibitors for use in Fragile X syndrome, Charcot Marie Tooth disease and Rett therapy. Dr. Kozikowski was also President of Vela Therapeutics focused on rapidly advancing therapies for these orphan indications. Dr. Kozikowski is world renown for his work on psychoactive substances including novel analogs of PCP and cocaine which showed potential to decrease harm to users.

Positions